Compare Citius Pharmaceuticals Inc (CTXR) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Fidelity National Information Servcs Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Fidelity National Information Servcs Inc trades at $34.04 (market cap $17.71B). The key difference: Fidelity National Information Servcs Inc is far larger — about 1300.3× Citius Pharmaceuticals Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Fidelity National Information Servcs Inc for 88 Days on average.
| CTXR | FIS | |
|---|---|---|
Market Cap | $13.62M | $17.71B |
Volume | 132,438 | 9,047,825 |
Sector | Health | Technology |
52-Week High | $1.82 | $68.57 |
52-Week Low | $0.48 | $32.44 |
Typical Hold Time | 17 Days | 88 Days |
Enterprise Value | $3.79M | $38.22B |
Dividend Yield | — | 5.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
FIS trades at $34.34, up 1.54% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 5.27 and P/S of 1.46, while profitability has improved significantly with net income margin reaching 27.65% in 2026 projections. Recent business developments include multiple core banking platform wins and new product launches, positioning the company for growth in financial technology modernization.
FIS presents a compelling value opportunity with strong analyst support (56.76% buy ratings) and a $47.15 consensus price target representing 37% upside. However, investors face risks from the company's elevated debt levels and inconsistent cash flow generation. The technical bearish signal and recent price weakness suggest potential near-term volatility despite fundamental improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
